{"id":"pre-implementation-baseline-including-opioid","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Sleep disturbances"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL4208783","moleculeType":"Small molecule","molecularWeight":"590.67"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Buprenorphine's partial agonist activity at the mu-opioid receptor reduces the risk of overdose and dependence compared to full opioid agonists. It also has a ceiling effect, limiting the maximum effect on opioid receptors, which helps to prevent excessive sedation and respiratory depression.","oneSentence":"Buprenorphine is a partial opioid agonist that works by activating opioid receptors in the brain, reducing the craving for opioids and alleviating withdrawal symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:53.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of opioid use disorder"},{"name":"Maintenance therapy for opioid dependence"}]},"trialDetails":[{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT07427043","phase":"PHASE3","title":"Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-01","conditions":"Opioid Consumption, Postoperative, Multimodal Analgesia, Robotic Assisted Laparoscopic Surgery","enrollment":300},{"nctId":"NCT04060303","phase":"PHASE3","title":"ENhanced Recovery in CHildren Undergoing Surgery","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2020-07-01","conditions":"Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis","enrollment":599},{"nctId":"NCT04944225","phase":"NA","title":"Opioid Reduction Strategy South Western Ontario","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-11-01","conditions":"Opioid Use","enrollment":100000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pre-implementation baseline including opioid","genericName":"pre-implementation baseline including opioid","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial opioid agonist that works by activating opioid receptors in the brain, reducing the craving for opioids and alleviating withdrawal symptoms. Used for Treatment of opioid use disorder, Maintenance therapy for opioid dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}